What is Engeneic?
Engeneic is at the forefront of oncology innovation, specializing in the research, development, and manufacturing of targeted anti-cancer treatments. Its proprietary EDV nanocell platform represents a first-in-class cyto-immunotherapy technology designed to directly target tumors while simultaneously activating the patient's immune system. The company is currently progressing through a Phase I/IIa clinical trial to evaluate the safety and efficacy of its EGFR-targeted EDV nanocells in individuals with advanced solid tumors. Engeneic's strategic objective is to bring its novel cancer therapies to market, aiming to significantly improve patient treatment outcomes.
How much funding has Engeneic raised?
Engeneic has raised a total of $18M across 3 funding rounds:
Private Equity
$1M
Series A
$7M
Series B
$10M
Private Equity (2011): $1M, investors not publicly disclosed
Series A (2014): $7M, investors not publicly disclosed
Series B (2014): $10M supported by Foley Ventures and GRT Capital Partners LLC
Key Investors in Engeneic
Foley Ventures
Foley Ventures is an independent venture capital fund that invests in a diverse range of industries, including software services, healthcare, and biotechnology. They support companies nationwide, focusing on entrepreneurs requiring venture capital.
What's next for Engeneic?
With the recent major strategic investment, Engeneic is poised to further its clinical development and manufacturing capabilities. The company's focus on its EDV nanocell platform, particularly for EGFR-targeted therapies in solid tumors, positions it for potential breakthroughs in cancer treatment. Future endeavors will likely involve expanding clinical trial phases, potentially seeking further strategic partnerships, and scaling up manufacturing processes to prepare for commercialization. This phase of growth is critical for validating the platform's therapeutic potential and navigating the complex regulatory landscape of novel cancer therapies.
See full Engeneic company page
